Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
100 hedge funds and large institutions have $193M invested in Aratana Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 14 closing their positions.
7,933% more call options, than puts
Call options by funds: $482K | Put options by funds: $6K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
46% more capital invested
Capital invested by funds: $133M → $193M (+$60.5M)
7% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 29
5% less funds holding
Funds holding: 105 → 100 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
+$8.32M |
| 2 |
Goldman Sachs
New York
|
+$2.45M |
| 3 |
GAI
General American Investors
New York
|
+$1.28M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.04M |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
+$708K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$1.56M |
| 2 |
Millennium Management
New York
|
-$1.19M |
| 3 |
BC
Broadfin Capital
New York
|
-$1.06M |
| 4 |
Renaissance Technologies
New York
|
-$586K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$584K |
PETX Hedge Fund Activity: Q3 2018 in Review
100 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2018, worth a combined $193M — up 46% from $133M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PETX and 9 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 31 added.
The largest buyer was Engaged Capital, adding an estimated $8.32M. The largest seller was William Blair & Company, cutting an estimated $1.56M.
- 100 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2018, down from 105 in Q2 2018.
- Funds reported $193M of Aratana Therapeutics, Inc. stock for Q3 2018, up 46% quarter-over-quarter.
- 9 funds opened new Aratana Therapeutics, Inc. positions in Q3 2018 and 14 closed out, a net change of -5 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q3 2018 was Engaged Capital, an estimated $8.32M added.
- The largest Aratana Therapeutics, Inc. seller in Q3 2018 was William Blair & Company, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2018.